Hartmannův Roztok B. Braun

Hartmannův Roztok B. Braun is an intravenous electrolyte solution containing potassium chloride, sodium chloride, calcium chloride dihydrate, and sodium lactate. It is supplied as a sterile solution for infusion, marketed in the European Union, and classified as a prescription‑only drug (Rx). The formulation is designed to replace extracellular fluid and restore electrolyte balance during medical situations that require fluid resuscitation in clinical practice and patient care.

Hartmannův Roztok B. Braun is indicated for the intravenous replacement of fluids and electrolytes in a variety of clinical settings, including emergency, surgical, and critical‑care environments.

- Fluid replacement in acute dehydration. - Electrolyte replenishment during peri‑operative management. - Treatment of hypovolemia associated with burns or trauma. - Supportive therapy for patients receiving large volumes of blood or plasma. - Management of metabolic acidosis when lactate conversion is desired. - Correction of electrolyte disturbances in renal replacement therapy. - Maintenance of electrolyte balance during intensive care unit (ICU) stays.

The safety profile of Hartmannův Roztok B. Braun reflects the typical reactions associated with intravenous electrolyte solutions. Most reactions are mild and self‑limiting, but clinicians monitor electrolyte levels and volume status during administration and adjust infusion rates as needed or discontinue.

Common: - Mild transient pain or irritation at the infusion site. - Slight increase in serum sodium or potassium levels that resolves without intervention. - Nausea or mild gastrointestinal discomfort. - Temporary hypervolemia leading to mild peripheral edema.

Serious: - Severe hyperkalemia causing cardiac arrhythmia. - Hypernatremia with neurologic symptoms such as confusion. - Calcium overload resulting in hypotension or cardiac dysfunction. - Metabolic alkalosis from excessive lactate metabolism.

When using Hartmannův Roztok B. Braun, healthcare professionals should observe several precautionary measures to minimize risks and ensure appropriate therapy.

- Verify patient’s baseline electrolyte concentrations and renal function before initiation. - Adjust infusion rate in patients with cardiac or pulmonary edema. - Avoid rapid administration in neonates and infants to prevent fluid overload. - Use caution in patients receiving potassium‑sparing diuretics or ACE inhibitors. - Monitor serum calcium levels when large volumes are infused. - Discontinue or modify therapy if signs of hypervolemia or electrolyte imbalance appear.

Hartmannův Roztok B. Braun may interact with other intravenously administered agents or medications that affect electrolyte balance.

Avoid: - Co‑administration with concentrated potassium chloride solutions, which can precipitate and cause catheter blockage. - Simultaneous infusion of calcium‑containing medications that may form insoluble complexes.

Use with caution: - Loop diuretics, which can amplify electrolyte shifts and require closer monitoring. - ACE inhibitors or ARBs, because they may increase the risk of hyperkalemia. - Blood products, as they can alter calcium and potassium levels during transfusion. - Sodium bicarbonate infusions, which can increase sodium load and affect acid‑base balance. - Renal replacement therapy, where electrolyte composition of the dialysate may require adjustment of the solution rate.